Composition comprises (a) at least one first compound comprising celecoxib etoricoxib lumiracoxib parecoxib rofecoxib valdecoxib valicoxib and (b) at least one second compound comprising: e.g. indoprofen ibuproxam ketoprofen ketorolac loxoprofen naproxen naproxen sodium oxaprozin pirprofen suprofen tiaprofenic acid and alminoprofen; salicylamide and salicyl salicylate; aceclofenac acemetacin and alclofenac; mefenamic acid flufenamic acid and meclofenamic acid; ampyrone azapropazone and clofezone...

The purpose of the present invention is to provide an osteogenesis promoter that can be administered locally and systemically and that is suitable for clinical application. Provided is an osteogenesis promoter that contains as an active ingredient at least one compound selected from the group consisting of phenazopyridine hydrochloride riluzole hydrochloride tranilast rabeprazole indoprofen nabumetone luteolin leflunomide lansoprazole methiazole thiabendazole albendazole tiaprofenic acid balsala...

Disclosed is the use of a prostaglandin (PH) compound of formula (II) where the substituents are as disclosed in the description

Disclosed is a solid oral dosage pharmaceutical tablet comprising a first layer including at least one opioid, the first layer disposed between two adjacent controlled release layers, at least one of said adjacent controlled release layers including at least one non-opioid analgesic, wherein: a. the two adjacent controlled release layers cover substantially the entire first layer around a peripheral edge thereof, and/or b. a portion of the two adjacent controlled release layers are joined into a...

The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monens...

The present invention relates to methods for enhancing Hypoxia inducible factor- 1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 36-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride 28-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate tilorone analogue R-9536-DA indoprofen ciclopiroxolamine tryptophan ansindione nabumetone oxybendazole albendazole tropicamide pramoxine hydrochloride atenolol mebendazole carbetapentane citrate monen...